PTPRT and cancer: In this study, prolonged mOS was observed in PTPRD/PTPRT mutant patients who received ICI treatment, compared with the WT, across multiple cancers in two independent ICI-treated cohorts, confirming the prediction ability of PTPRD/PTPRT mutations for the efficiency of ICI treatment.